Single agent bevacizumab for myelofibrosis: results of the Myeloproliferative Disorders Research Consortium Trial
Single agent bevacizumab for myelofibrosis: results of the Myeloproliferative Disorders Research Consortium Trial
复制标题
DOI：
10.3324/haematol.2012.083337
复制
发表时间：
2013-09-01
期刊：
影响因子：
10.1
通讯作者：
Hoffman, Ronald
中科院分区：
文献类型：
--
作者：
Mesa, Ruben A.;Silver, Richard T.;Hoffman, Ronald
骨髓增生性肿瘤，骨髓纤维化，是一种病态和经常致命的疾病，包括原发性骨髓纤维化，终末期原发性血小板增多症和红细胞增多症。贝伐单抗（15mg /kg静脉注射，每21天一次）在骨髓增生性疾病研究联盟进行的II期国际试验中进行了测试。13名患者参加了这项两期试验的第一阶段。在接受治疗的11例患者中，只有3例患者接受了4个疗程以上的治疗；没有一个病人达到客观反应。此外，在其他疾病状态下，观察到与抗vegf单克隆抗体制备相关的血管或胃肠道事件不直接相关的显著毒性。缺乏客观反应加上毒性导致决定提前终止研究。如果未来的研究将贝伐单抗纳入骨髓纤维化的联合治疗，则应考虑更适度的剂量。
The myeloproliferative neoplasm, myelofibrosis, is a morbid and frequently fatal illness encompassing primary myelofibrosis, and end-stage essential thrombocythemia and polycythemia. Bevacizumab (15 mg/kg intravenous (i.v.) every 21 days) was tested in a phase II international trial conducted by the Myeloproliferative Disorders Research Consortium. Thirteen patients were enrolled in the first stage of this 2-stage trial. Among the 11 patients who received therapy, only 3 received more than 4 cycles of therapy; none of the patients achieved an objective response. Furthermore, significant toxicity, not directly related to the vascular or gastrointestinal events typically associated with the anti-VEGF monoclonal antibody preparation in other disease states, was observed. Lack of objective responses coupled with toxicity led to the decision to terminate the study early. If future studies incorporate bevacizumab in combination therapy for myelofibrosis, more modest doses should be considered.